Share on StockTwits

Analysts at Canaccord Genuity lifted their target price on shares of DexCom (NASDAQ:DXCM) to $44.00 in a research report issued to clients and investors on Friday, StockRatingsNetwork reports. Canaccord Genuity’s price objective points to a potential upside of 19.66% from the company’s current price.

In other DexCom news, CFO Jess Roper unloaded 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $37.38, for a total value of $299,040.00. Following the sale, the chief financial officer now directly owns 65,808 shares of the company’s stock, valued at approximately $2,459,903. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

DexCom (NASDAQ:DXCM) traded down 2.01% during mid-day trading on Friday, hitting $36.03. 276,193 shares of the company’s stock traded hands. DexCom has a 52 week low of $14.05 and a 52 week high of $38.20. The stock has a 50-day moving average of $35.31 and a 200-day moving average of $29.52. The company’s market cap is $2.586 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.04. The company had revenue of $42.90 million for the quarter, compared to the consensus estimate of $35.90 million. During the same quarter last year, the company posted ($0.25) earnings per share. DexCom’s revenue was up 85.7% compared to the same quarter last year. On average, analysts predict that DexCom will post $-0.46 earnings per share for the current fiscal year.

DXCM has been the subject of a number of other recent research reports. Analysts at Benchmark Co. raised their price target on shares of DexCom from $40.00 to $44.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Separately, analysts at Raymond James reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $34.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $32.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $32.10.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.